Although some studies report a numerical trend toward higher VTE rates with higher doses of JAK inhibitors, these observations have not reached statistical significance, and absolute event rates remain low [ 51 ].
← all excerpts
A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients?
1
—
—